IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
Cheng, Ann-Lii; Cornelio, Gerardo H.; Shen, Lin; Price, Timothy Jay; Yang, Tsai-Shen; Chung, Ik-Joo; Dai, Guanghai; Lin, Jen-Kou; Sharma, Atul; Yeh, Kun-Huei; Ma, Brigette; Zaatar, Adel; Guan, Zhongzhen; Masood, Nehal; Srimuninnimit, Vichien; Yau, Thomas Cheung; Sarholz, Barbara; Lim, Robert S. C.
刊名JOURNAL OF CLINICAL ONCOLOGY
2013-05-20
suppl.S期:15
收录类别SCI ; ISTP
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
语种英语
WOS记录号WOS:000335419603483
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56699
专题北京大学临床肿瘤学院
作者单位1.Natl Taiwan Univ Hosp, Taipei, Taiwan
2.San Juan De Dios Hosp, Pasay City, Philippines
3.Peking Univ, Canc Hosp, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China
4.Queen Elizabeth Hosp, Adelaide, SA, Australia
5.Chang Gung Mem Hosp, Taoyuan, Taiwan
6.Chonnam Natl Univ, Hawsun Hosp, Hwasuneup, South Korea
7.Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
8.Taipei Vet Gen Hosp, Taipei, Taiwan
9.All India Inst Med Sci, New Delhi, India
10.Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China
11.Mt Miriam Canc Hosp, George Town, Malaysia
12.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
13.Aga Khan Univ & Hosp, Karachi, Pakistan
14.Siriraj Hosp, Bangkok, Thailand
15.Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
16.Merck KGaA, Darmstadt, Germany
17.Natl Univ Hlth Syst, Singapore, Singapore
推荐引用方式
GB/T 7714
Cheng, Ann-Lii,Cornelio, Gerardo H.,Shen, Lin,et al. Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).[J]. JOURNAL OF CLINICAL ONCOLOGY,2013,suppl.S(15).
APA Cheng, Ann-Lii.,Cornelio, Gerardo H..,Shen, Lin.,Price, Timothy Jay.,Yang, Tsai-Shen.,...&Lim, Robert S. C..(2013).Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC)..JOURNAL OF CLINICAL ONCOLOGY,suppl.S(15).
MLA Cheng, Ann-Lii,et al."Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).".JOURNAL OF CLINICAL ONCOLOGY suppl.S.15(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Cheng, Ann-Lii]的文章
[Cornelio, Gerardo H.]的文章
[Shen, Lin]的文章
百度学术
百度学术中相似的文章
[Cheng, Ann-Lii]的文章
[Cornelio, Gerardo H.]的文章
[Shen, Lin]的文章
必应学术
必应学术中相似的文章
[Cheng, Ann-Lii]的文章
[Cornelio, Gerardo H.]的文章
[Shen, Lin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。